Abstract 54P
Background
Lymph nodes (LN) are the most frequent metastasis sites in oesophageal squamous cell carcinoma (ESCC), but the associated mechanisms are poorly understood. Tumor cells seed and survive at LN during the early adaptation step, which is the bottleneck for successful metastasis. However, the phenotypic and molecular characteristics of heterogeneous metastatic cells that contribute to such a challenging process remain elusive.
Methods
We established a human xenograft spontaneous LN metastasis model to capture tumor cell dissemination behaviors. We conducted single-cell RNA sequencing on tumor cells collected from primary tumors and metastatic LN to profile the dynamic cellular and molecular changes in tumor cells associated with LN metastasis. We further identified and characterized the early metastasis tumor cells in LN through in vitro and in vivo functional assays.
Results
We revealed that LN metastasis is initiated by rare ESCC subpopulations with stemness and mesenchymal regulatory gene expression signatures. These tumor cell subpopulations are critical to driving metastasis in distant organs through the blood circulation in mice, supporting the metastasis-initiating cells (MICs) properties. Importantly, these key driver cells were observed to convert the metabolic strategy to mitochondrial oxidative phosphorylation (OXPHOS) during cell seeding in the LN. Enhanced OXPHOS in LN metastatic cells is induced by fatty acids and regulated by NRF2 signaling. Pharmacological inhibition of OXPHOS with IACS-010759 markedly attenuated metastasis in mice.
Conclusions
Our results demonstrate the important role of mitochondrial OXPHOS in promoting ESCC metastasis and suggest the clinical therapeutic potential of OXPHOS inhibitors for preventing metastatic spread in ESCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (82103643, 82072738, 82072731).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09